Although activating KRAS mutations occur frequently in cancer ... anticancer targets — and that are crucial in cancer cells dependent on activated KRAS.

Groups partner on research project to test innovative new treatment for KRAS-mutant cancer being developed at Hebrew ...

Amgen is facing a slowdown in uptake of its first-to-market KRAS inhibitor Lumakras as a second-line therapy for KRAS-mutated non-small cell lung cancer (NSCLC), so is understandably excited by ...